Health Condition 1: null- Partial thickness rotator cuff tear of shoulder joint. Health Condition 2: M751- Rotator cuff tear or rupture, notspecified as traumatic
Conditions
Interventions
Intervention1: SUPRASCAPULAR NERVE BLOCK: SUPRASCAPULAR NERVE BLOCK BY USING 0.25% BUPIVACAINE, DEPOT METHYLPREDNISOLONE, 2% LIGNOCAINE
Control Intervention1: UST: ultrasonic therapy over the shoulder
Sponsors
IPGMER SSKM Hospital
Eligibility
Inclusion criteria
Inclusion criteria: (1) Clinical rotator cuff pathology and partial tear confirmed by ultrasonography or Magnetic Resonance Imaging. (2) Symptoms persisting for at least 4 weeks duration. (3) Pain defined as a score of 5 points or more on a 10-cm visual analog scale (VAS) rated from 0 (no pain) to 10 (worst imaginable pain). (4) Patient mentally sound enough to communicate and participate in the study and can understand the parameters well.
Exclusion criteria
Exclusion criteria: (1)Long standing ( >16weeks) symptoms. (2) Arm Drop Sign positive. (3) Full thickness tears of the rotator cuff in ultrasonographic examination or MRI. (4) The presence of another obvious associated cause for the pain (i.e., Primary osteoarthritis of glenohumeral joint, fracture, radiculopathy, myofascial pain, central neuropathic pain) (5) Severe motor weakness (muscle power of deltoid less than grade 2 on the manual muscle test). (6) Patients with Post myocardial infarction, Post stroke, Post mastectomy, prolonged immobilization. (7) The presence of an unstable medical condition or a known uncontrolled systemic disease, including cancer, diabetes, rheumatoid arthritis, endocrine disease, major depression, schizophrenia, & patients with persistent very high level of ESR & CRP. (8) Patients with contraindications for UST i.e. infection in and around the joint, bacteraemia or sepsis, significant skin breakdown at the proposed therapy site, presence of a joint prosthesis etc. (9)Patients with contraindications of steroid injections i.e. overlying soft tissue sepsis, bacteraemia, anatomic inaccessibility, uncooperative patient, uncontrolled bleeding diathesis etc. (10)Patients who got intra-articular injection in shoulder within last six months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SPADITimepoint: BASELINE, 2WEEKS, 4WEEKS, 8WEEKS | — |
Secondary
| Measure | Time frame |
|---|---|
| VAS, RANGE OF MOTIONTimepoint: BASELINE, 2WEEKS, 4WEEKS, 8WEEKS | — |
Countries
India
Contacts
Public ContactAmbar Konar
I.P.G.M.E.R.
Outcome results
None listed